TrialBMC cancer2019

Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene.

Iben Kümler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.